Janux Therapeutics, Inc. 8-K

What Happened
Janux Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 by issuing a press release on May 7, 2026. The company furnished the press release as Exhibit 99.1 to an 8-K; the filing was signed by David Campbell, Ph.D., President and Chief Executive Officer. The information in the 8-K and the attached press release is furnished (not “filed”) under the Exchange Act.

Key Details

• Date of disclosure: May 7, 2026.
• Reporting period: quarter ended March 31, 2026.
• Exhibit: Press release attached as Exhibit 99.1 to the Form 8-K.
• Legal/formal note: the press release information is furnished and not subject to Section 18 liabilities.

Why It Matters
Quarterly financial results are material to investors because they provide updated information on the company’s operating performance and can affect the stock price and investor decisions. Because the 8-K furnishes a press release rather than filing it, investors should review the attached Exhibit 99.1 for the specific earnings, revenue, cash position, or guidance details cited by the company.